| 引用本文:唐金莉，李杰.参附注射液对缺血性心肌病伴急性心力衰竭患者心功能和心肌纤维化的影响[J].世界中医药,2018,(09):. |
|
| 参附注射液对缺血性心肌病伴急性心力衰竭患者心功能和心肌纤维化的影响 |
| Randomized Controlled Trial of Shenfu Injection on Cardiac Function and Myocardial Fibrosis in Patients with Ischemic Cardiomyopathy and Acute Heart Failure |
| 投稿时间：2018-06-25 |
| DOI：10.3969/j.issn.1673-7202.2018.09.022 |
| 中文关键词: 参附注射液 缺血性心肌病 急性心力衰竭 心功能 心肌纤维化 |
| English Keywords:Shenfu Injection Ischemic cardiomyopathy Acute heart failure Cardiac function Myocardial fibrosis |
| 基金项目:山东省济宁市科研项目（2016213） |
|
| 摘要点击次数: 758 |
| 全文下载次数: 731 |
| 中文摘要: |
| 目的：探讨参附注射液对缺血性心肌病伴急性心力衰竭患者心功能及心肌纤维化的影响。方法：选取2015年2月至2017年11月山东省兖矿集团有限公司总医院收治的缺血性心肌病伴急性心力衰竭患者68例，按照随机数字表法分为对照组和观察组，每组34例。2组患者均给予常规西药治疗，观察组在对照组基础上增加参附注射液治疗，连续给药2周。评估治疗后2组患者临床疗效，观察并比较2组患者治疗前后心功能及心肌纤维化变化。结果：观察组总有效率为94.12%，明显高于对照组的76.47%（P<0.05）。治疗后2组左心室舒张末期内径（LVEDD）、左心室收缩末期内径（LVESD）、左心室舒张末期容积（LVEDV）、左心室收缩末期容积（LVESV）均明显减小，且观察组明显小于对照组（P<0.05）；2组左心室射血分数（LVEF）均明显增加，且观察组明显高于对照组（P<0.05）。治疗后2组血清Ⅰ型/Ⅲ型前胶原（PCⅠ/PCⅢ）、透明质酸（HA）、层粘连蛋白（LN）及半乳凝素-3（Gal-3）等心肌纤维化均明显降低，且观察组明显低于对照组（P<0.05）。结论：参附注射液可明显改善缺血性心肌病伴急性心力衰竭患者心功能，降低心肌纤维化程度，提高总体临床疗效。 |
| English Summary: |
| To study the effects of Shenfu Injection on cardiac function and myocardial fibrosis in patients with ischemic cardiomyopathy and acute heart failure.Methods:A total of 68 patients with ischemic cardiomyopathy and acute heart failure treated in Yankuang Group General Hospital from February 2015 to November 2017 were selected and divided into control group and observation group according to the random table method,with 34 cases in each group.Both groups were given conventional medicine,the observation group was additionally given Shenfu Injection on the basis of this treatment for 2 weeks.The clinical efficacy of both groups was evaluated after treatment.The changes of cardiac function indexes and the levels of myocardial fibrosis indexes in both groups were observed and compared before and after treatment.Results:The total effective rate of observation group was 94.12%,which was significantly higher than 76.47% of control group (P<0.05).The LVEDD,LVESD,LVEDV and LVESV of both groups significantly decreased after treatment,and observation group decreased more significantly than control group (P<0.05 or P<0.01).The LVEF of both groups significantly increased,and observation group increased more significantly than the control group (P<0.01).After treatment,the levels of myocardial fibrosis indexes such as PCⅠ,PCⅢ,HA,LN and Gal-3 in both groups significantly decreased,and observation group decreased more significantly than control group (P<0.05 or P<0.01).Conclusion:Shenfu Injection can significantly improve cardiac function of patients with ischemic cardiomyopathy and acute heart failure,reduce the degree of myocardial fibrosis,and improve the overall clinical efficacy. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
